Anti-tumor necrosis factor therapy: The Australian experience

APLAR Journal of Rheumatology

Volumn 9, Issue 2, 2006, Pages 119-123

  Nash, Peter ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adverse effects; Anti TNF agents; Guidelines; Registry

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; AUSTRALIA; DEMYELINATING DISEASE; DRUG BINDING; DRUG INDICATION; HUMAN; INJECTION SITE REACTION; LUPUS LIKE SYNDROME; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; MULTIPLE SCLEROSIS; NEUTROPENIA; PANCYTOPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; RHEUMATIC DISEASE; SEPSIS; SINGLE DRUG DOSE; SKIN CANCER;

EID: 33745948111     PISSN: 02190494     EISSN: 14798077     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2006.197_1.x     Document Type: Article

References (23)

1. Moreland LW, Schiff MH, Baumgartner SW, et al. (1999) Etanercept therapy in rheumatoid arthritis: A randomised, controlled study. Ann Intern Med 130, 478-86.
2. Maini RN, Breedveld FC, Kalden JR, et al. (1998) Therapeutic efficacy of multiple infusions of anti-tumour necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheumatism 41, 1552-63.
3. Lipsky PE, Van Der Heijde DMFM, St Claire EW, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343, 1594-602.
4. Bathon JM, Martin RW, Fleischmann RM, et al. (2000) A comparison of etanercept and methotrexate in patients with early rehumatiod arthritis. N Engl J Med 343, 1586-93.
5. Moreland LW, Baumgartner SW, Schiff MH, et al. (1997) Treatment of rheumatoid arthritis with a recombinant human tumornecrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337, 141-7.
6. Weinblatt ME, Kremer JM, Bankhurst AD, et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340, 253-9.
7. Maini R, St Clair EW, Breedveld F, et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group Lancet 354, 1932-9.
8. Keystone EC, Kavanaugh AF, Sharp JT, et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50, 1400-11.
9. Davis JC Jr, Van Der Heijde D, Braun J, et al. Ankylosing Spondylitis Study Group. (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 48, 3230-6.
10. Braun J, Brandt J, Zink A, et al. (2002) Treatment of ankylosing spondylitis with infliximab: A randomized controlled multicentre trial. Lancet 359, 1187-93.
11. Haibel H, Rudwaleit M, Brandt HC, et al. (2006) Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 54, 678-81.
12. Mease P, Goffe B, Metz J, et al. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 356, 385-90.
13. Antoni CE, Kavanaugh A, Kirkham B, et al. (2005) Related Articles, Links Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52, 1227-36.
14. Kavanaugh A, Antoni CE, Gladman DD, et al. (2006) The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results of radiographic analyses after 1 year. Ann Rheum Dis.
15. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52, 3279-89.
16. Bewtra M, Lichtenstein GR. (2005 April) Infliximab use in Crohn's disease. Expert Opin Biol Ther 5, 589-99.
17. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 130, 323-33.
18. Provenzano C, Ferrante MC, Simon G. (2005) TB screening and anti-TNF alpha treatment. Thorax 60, 613.
19. Ormerod LP. (2004) Assessing risk and managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNFalpha treatment. Cytokine 28, 4-5.
20. Lu C, Williams K, Day R. (2006) Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: Are we on target? Intern Med J 36, 19-27.
21. Kvien TK, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvag BY, Rodevand E. (2005) A Norwegian DMARD register: Prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 23 (5 Suppl 39), S188-94.
22. Geborek P, Bladstrom A, Turesson C, et al. (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64, 699-703.
23. Symmons D, Silman A. (2006) The World of Biologics. Lupus 15, 122-6.